Akso Health Group ADS (AHG) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Akso Health Group ADS (NASDAQ: AHG) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.26 (-5.26% 1D, market cap $1.14B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1011 tracked Consumer Discretionary issuers, AHG ranks #823 in composite RQD confidence.
Within the Consumer Discretionary sector (Business Services), AHG carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of -0.1%, and ROIC of —. By comparison, RSKD (Riskified Ltd. (Class A)) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -20.3%, cap $1.22B) and QNST (QuinStreet Inc.) posts a B- grade (70/100 RQD, P/E N/A, ROIC 2.6%, cap $980.8M). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).
Per AHG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001702318), Akso Health Group ADS generated $13.8M in revenue (-6.4% YoY), -$18.7M in net income, and -$12.8M in free cash flow against $212.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While AHG currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Consumer Discretionary with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.03) and Max Pain ($1.32) forces dealer call-delta covering toward $2.63.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Akso Health Group ADS (AHG) dropped -5.26% to $1.26, trading at 32% of its 52-week range ($0.68 – $2.5). Stretched risk/reward at current multiples (-0% profit margin) under elevated 10-year interest-rate pressure.
Akso Health Group has seen sharp swings in recent years, and the latest moves raise a simple question for you as a shareholder or potential buyer. Is the current share price in line with what the company’s book value can
In July 2026, Akso Health Group reported full-year results for the period ended March 31, 2026, showing sales of US$13.84 million and a net loss of US$18.67 million, alongside materially lower loss per share than a year
Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the commencement of its next-generation, proprietary Brain-Computer Interface (BCI) technology research and development program. The Compan
Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Adopting an i
Yahoo Finance coverage on AHG stock catalysts, institutional flow, and earnings outlook.
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9LTXc1MURydmdGcFBPc0xqZ3N2MFJLaXd0Zy1IS1VfdU4tMXV2RU50aDJwS3AwQkhLUTF6ZUdoUXFvbDhOQ0oxYVRyc3BrYXFyWnE3YjZkVU0zbG1EVXdrX2NudDdVN2VwYmQ0YkNOcmpNem04cnFB?oc=5"
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOSmF3UjZRbjRRWEdaZGhYcXIxbExRLXM1Ui05Zk9IcmpuSEdoQ19NSzhuWHJ5QTJ1bjMxY3hQbXloNFFteUFTb2ljVnItVUJPbFRzRlVmSjZGajlDa0FGeEUzNG4xS0VQbEZjekFORm9NOS1OT0FmSWFfMXV
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNaE9ub2pGWnhKcE9QQjV0NjdnTGxpNUMyUm9aMllGS0NiLUNqcGZnYk5LbGFCUTNqRkdHQVJLM1FQLVZvZVNmcXUyMmdDWkd0bE9NM0FSNl84Y3EyU2pBZjZHekNDTVFYQUV4ZnIwZUcwckEwbFBVdU4tc2x
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZkZORTU4TkJqNzliOXNfZHdmVGlSdFJaYXJBN2gtY0o4WlVYeXlPWVZDMnE5QTY1akdpUDRfYWdaY0FISE1hb0pXSWhJZzh2UUVaMktFbEhOeVUxMkFyaXY3WnF3SGRWWHUtS2V5QV9fZTBIMXZycGtxRC1
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPbHhrd0hWc1pRV1lKXzBJVnBZajBtaGx3YXpEUDNlaWR2T085T3hnSzBrWDlhaFJyaHBKbHZublA1SDZCbU1fT0htVkRTUTJZOEtZNEF6ZkdJeWNRNERzZE5CODZTblpTeHNhNkUzVnlXMFlIRDB0a0FidlN
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -6.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AHG today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AHG. Explore sector supply chains on /butterfly.
Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, Akso Health Group ADS (AHG) ranks #823 by composite RQD confidence (34/100, grade E) and #499 by equity capitalization ($1.14B). Within this direct 5-issuer industry benchmark cohort, NUTX leads on earnings valuation at 20.3x trailing P/E, while NUTX leads on capital efficiency and profitability with 85.0% ROIC and 50.8% gross margin. NUTX currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with AHG at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AHG
ACTIVE
Akso Health Group ADS | E | 34/100 | — | -0.1% | — | -5.26% | $1.14B | Benchmark Subject |
| RSKD Riskified Ltd. (Class A) | D+ | 55/100 | — | 51.7% | -20.3% | -4.67% | $1.22B | /rskd-vs-ahg → |
| QNST QuinStreet Inc. | B- | 70/100 | — | 10.1% | 2.6% | +1.52% | $980.8M | /qnst-vs-ahg → |
| LQDT Liquidity Services Inc. | B | 74/100 | 50.5x | 43.8% | 12.9% | -1.48% | $1.42B | /lqdt-vs-ahg → |
| NUTX Nutex Health Inc. | A | 86/100 | 20.3x | 50.8% | 85.0% | -4.74% | $1.44B | /nutx-vs-ahg → |
In its most recent audited fiscal period (FY2025, filed 2026-03-31), Akso Health Group ADS (AHG) reported GAAP revenue of $13.8M (-6.4% vs. FY2024 revenue of $14.8M , and +472.9% cumulative change since FY2023) , GAAP net income of -$18.7M, operating cash flow of -$12.8M, and free cash flow of -$12.8M (-1350.9% YoY). On the balance sheet, AHG closed FY2025 with $212.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $13.8M | -$18.7M | -$12.8M | -$12.8M | $212.0M | — |
| FY2024 (FY) | 2025-03-31 | $14.8M | -$135.0M | $1.2M | $1.0M | — | — |
| FY2023 (FY) | 2024-03-31 | $2.4M | -$9.5M | $1.4M | $1.4M | — | — |
As of 2026-11-02, Akso Health Group ADS (NASDAQ: AHG) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.26 (-5.26% 1D, market cap $1.14B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1011 tracked Consumer Discretionary issuers, AHG ranks #823 in composite RQD confidence.
Within the Consumer Discretionary sector (Business Services), AHG carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of -0.1%, and ROIC of —. By comparison, RSKD (Riskified Ltd. (Class A)) holds a D+ grade (55/100 RQD, P/E N/A, ROIC -20.3%, cap $1.22B) and QNST (QuinStreet Inc.) posts a B- grade (70/100 RQD, P/E N/A, ROIC 2.6%, cap $980.8M). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).
Per AHG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001702318), Akso Health Group ADS generated $13.8M in revenue (-6.4% YoY), -$18.7M in net income, and -$12.8M in free cash flow against $212.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Discretionary with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
AHG last traded at $1.26 (-5.26% on volume of 4,899 shares), positioning the stock +22.33% above its 50-day simple moving average ($1.03) and -16.56% below its 200-day simple moving average ($1.51). Across its 52-week range of $0.68 to $2.50, AHG sits at the 31.9% percentile with a 14-day RSI of 57.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.10 to $1.42).
Why AHG Stock dropped -5.26% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-0% profit margin) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, AHG holds a score of 34 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 8 out of 20, with ROIC at 0% and an FCF yield of -1.12%, indicating the business is not currently converting capital into returns or positive free cash flow. The whale 13F flow pillar scores 10 out of 20, reflecting institutional accumulation and options positioning that is weaker than the top of the scale. Insider conviction scores 3 out of 20, the lowest pillar, drawn from the SEC Form 4 and Congressional PTR cluster flow. Macro regime fit scores 5 out of 20 with a beta of 1.0 and sector sensitivity noted. Forensic balance sheet scores 8 out of 20, citing an Altman Z of 2.5, a Piotroski F of 2 out of 9, and a Debt/Equity of 0.5. For a prospective investor, the upside case rests on any reversal in cash generation, which the rating does not currently show, while the valuation tradeoff is that a low share price alone does not offset negative returns on capital. The cumulative pillar profile signals elevated forensic risk and weak insider conviction rather than a constructive setup.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $13.8M | $-20.7M | $-18.7M | N/A | $-12.8M | N/A | N/A |
| FY 2024 | $14.8M | $-166.3M | $-135.0M | N/A | $1.0M | N/A | N/A |
| FY 2023 | $2.4M | $-8.6M | $-9.5M | N/A | $1.4M | N/A | N/A |
Per the SEC financials, operating margin is -60% and net margin is -60%, with gross margin at -0.1% in the market data. ROIC is 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, per the Roarable RQD rating. Debt/Equity is 0.5 per the same source. Cash and debt balances are not available in source data for any reported period.
Real-time company headlines, analyst actions, and sector developments for Akso Health Group ADS (AHG) • Click "Debate This Headline" to argue it in the Roar Pit below
Akso Health Group has seen sharp swings in recent years, and the latest moves raise a simple question for you as a shareholder or potential buyer. Is the current share price in line with what the company’s book value can
In July 2026, Akso Health Group reported full-year results for the period ended March 31, 2026, showing sales of US$13.84 million and a net loss of US$18.67 million, alongside materially lower loss per share than a year
Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the commencement of its next-generation, proprietary Brain-Computer Interface (BCI) technology research and development program. The Compan
Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Adopting an i
Yahoo Finance coverage on AHG stock catalysts, institutional flow, and earnings outlook.
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE9LTXc1MURydmdGcFBPc0xqZ3N2MFJLaXd0Zy1IS1VfdU4tMXV2RU50aDJwS3AwQkhLUTF6ZUdoUXFvbDhOQ0oxYVRyc3BrYXFyWnE3YjZkVU0zbG1EVXdrX2NudDdVN2VwYmQ0YkNOcmpNem04cnFB?oc=5"
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxOSmF3UjZRbjRRWEdaZGhYcXIxbExRLXM1Ui05Zk9IcmpuSEdoQ19NSzhuWHJ5QTJ1bjMxY3hQbXloNFFteUFTb2ljVnItVUJPbFRzRlVmSjZGajlDa0FGeEUzNG4xS0VQbEZjekFORm9NOS1OT0FmSWFfMXV
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNaE9ub2pGWnhKcE9QQjV0NjdnTGxpNUMyUm9aMllGS0NiLUNqcGZnYk5LbGFCUTNqRkdHQVJLM1FQLVZvZVNmcXUyMmdDWkd0bE9NM0FSNl84Y3EyU2pBZjZHekNDTVFYQUV4ZnIwZUcwckEwbFBVdU4tc2x
Welcome to the AHG (Akso Health Group ADS) Roar Pit. Current RQD Composite is 34/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Business Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on AHG, but look at what you are paying: current EV/EBITDA multiples with -0.1% gross margins. Unless Akso Health Group ADS expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on AHG, the market is fixating on short-term headline noise in Business Services and ignoring the balance sheet and cash flow trajectory. At $1.33 (52-wk range $0.68 - $2.50), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).